Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential

被引：33
作者：
Perla, Alexandre [1 ,2 ]
Fratini, Livia [1 ,2 ]
Cardoso, Paula S. [1 ,2 ]
Nor, Carolina [3 ,4 ]
Brunetto, Andre T. [1 ,5 ]
Brunetto, Algemir L. [1 ,5 ]
de Farias, Caroline Brunetto [1 ,5 ]
Jaeger, Mariane [1 ,5 ]
Roesler, Rafael [1 ,2 ]
机构：
[1] Univ Fed Rio Grande do Sul, Clin Hosp CPE HCPA, Expt Res Ctr, Canc & Neurobiol Lab, Porto Alegre, RS, Brazil
[2] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Pharmacol, Porto Alegre, RS, Brazil
[3] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON, Canada
[4] Hosp Sick Children, Dev & Stem Cell Biol Program, Toronto, ON, Canada
[5] Childrens Canc Inst, Porto Alegre, RS, Brazil
来源：
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2020年 / 8卷
关键词：
medulloblastoma; ependymoma; glioma; histone deacetylase inhibitors; epigenetics; brain tumor; CENTRAL-NERVOUS-SYSTEM; TERATOID RHABDOID TUMOR; PHASE-I CONSORTIUM; INDUCE CELL-DEATH; STEM-CELLS; MEDULLOBLASTOMA CELLS; IONIZING-RADIATION; EPIGENETIC CHANGES; ANTITUMOR-ACTIVITY; INDUCED APOPTOSIS;
D O I：
10.3389/fcell.2020.00546
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Brain cancers are the leading cause of cancer-related deaths in children. Biological changes in these tumors likely include epigenetic deregulation during embryonal development of the nervous system. Histone acetylation is one of the most widely investigated epigenetic processes, and histone deacetylase inhibitors (HDACis) are increasingly important candidate treatments in many cancer types. Here, we review advances in our understanding of how HDACis display antitumor effects in experimental models of specific pediatric brain tumor types, i.e., medulloblastoma (MB), ependymoma (EPN), pediatric high-grade gliomas (HGGs), and rhabdoid and atypical teratoid/rhabdoid tumors (ATRTs). We also discuss clinical perspectives for the use of HDACis in the treatment of pediatric brain tumors.
引用
收藏
页数：14
相关论文
共 136 条
  • [1] Imprinted CDKN1C Is a Tumor Suppressor in Rhabdoid Tumor and Activated by Restoration of SMARCB1 and Histone Deacetylase Inhibitors
    Algar, Elizabeth M.
    Muscat, Andrea
    Dagar, Vinod
    Rickert, Christian
    Chow, C. W.
    Biegel, Jaclyn A.
    Ekert, Paul G.
    Saffery, Richard
    Craig, Jeff
    Johnstone, Ricky W.
    Ashley, David M.
    [J]. PLOS ONE, 2009, 4 (02):
  • [2] Combined Treatments with a Retinoid Receptor Agonist and Epigenetic Modulators in Human Neuroblastoma Cells
    Almeida, Viviane Rosner
    Vieira, Igor Araujo
    Buendia, Marienela
    Brunetto, Andre Tesainer
    Gregianin, Lauro J.
    Brunetto, Algemir Lunardi
    Klamt, Fabio
    de Farias, Caroline Brunetto
    Abujamra, Ana Lucia
    da Costa Lopez, Patricia Luciana
    Roesler, Rafael
    [J]. MOLECULAR NEUROBIOLOGY, 2017, 54 (10) : 7610 - 7619
  • [3] Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG
    Anastas, Jamie N.
    Zee, Barry M.
    Kalin, Jay H.
    Kim, Mirhee
    Guo, Robyn
    Alexandrescu, Sanda
    Blanco, Mario Andres
    Giera, Stefanie
    Gillespie, Shawn M.
    Das, Jayanta
    Wu, Muzhou
    Nocco, Sarah
    Bonal, Dennis M.
    Quang-De Nguyen
    Suva, Mario L.
    Bernstein, Bradley E.
    Alani, Rhoda
    Golub, Todd R.
    Cole, Philip A.
    Filbin, Mariella G.
    Shi, Yang
    [J]. CANCER CELL, 2019, 36 (05) : 528 - +
  • [4] The interplay of epigenetic marks during stem cell differentiation and development
    Atlasi, Yaser
    Stunnenberg, Hendrik G.
    [J]. NATURE REVIEWS GENETICS, 2017, 18 (11) : 643 - 658
  • [5] Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors
    Autin, Pierre
    Blanquart, Christophe
    Fradin, Delphine
    [J]. CANCERS, 2019, 11 (10)
  • [6] The developmental origin of brain tumours: a cellular and molecular framework
    Azzarelli, Roberta
    Simons, Benjamin D.
    Philpott, Anna
    [J]. DEVELOPMENT, 2018, 145 (10):
  • [7] Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets
    Bahmad, Hisham F.
    Poppiti, Robert J.
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2020, 73 (05) : 243 - 249
  • [8] Drug repurposing towards targeting cancer stem cells in pediatric brain tumors
    Bahmad, Hisham F.
    Elajami, Mohamad K.
    El Zarif, Talal
    Bou-Gharios, Jolie
    Abou-Antoun, Tamara
    Abou-Kheir, Wassim
    [J]. CANCER AND METASTASIS REVIEWS, 2020, 39 (01) : 127 - 148
  • [9] Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas
    Bayliss, Jill
    Mukherjee, Piali
    Lu, Chao
    Jain, Siddhant U.
    Chung, Chan
    Martinez, Daniel
    Sabari, Benjamin
    Margol, Ashley S.
    Panwalkar, Pooja
    Parolia, Abhijit
    Pekmezci, Melike
    McEachin, Richard C.
    Cieslik, Marcin
    Tamrazi, Benita
    Garcia, Benjamin A.
    La Rocca, Gaspare
    Santi, Mariarita
    Lewis, Peter W.
    Hawkins, Cynthia
    Melnick, Ari
    Allis, C. David
    Thompson, Craig B.
    Chinnaiyan, Arul M.
    Judkins, Alexander R.
    Venneti, Sriram
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (366)
  • [10] Epigenetics and survivorship in pediatric brain tumor patients
    Bhattacharya, Debanjan
    Pomeroy, Scott L.
    Pomeranz Krummel, Daniel A.
    Sengupta, Soma
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2020, 150 (01) : 77 - 83
12345678910